Literature DB >> 11520247

Gene therapy for colorectal cancer: therapeutic potential.

M J Chen1, G A Chung-Faye, P F Searle, L S Young, D J Kerr.   

Abstract

Colorectal cancer is a leading cause of cancer mortality in Western countries. Gene therapy has been proposed as a potential novel treatment modality for colorectal cancer, but it is still in an early stage of development. The preclinical data have been promising and numerous clinical trials are underway. This brief review aims to summarise the current status of clinical trials of different gene therapy strategies, including immune stimulation, mutant gene correction, prodrug activation and oncolytic virus therapy, for patients with colorectal cancer. Data from phase I trials have proven the safety of the reagents but have not yet demonstrated significant therapeutic benefit. In order to achieve this and extend the scope of the treatment, continuing efforts should be made to improve the antitumour potency, efficiency of gene delivery and accuracy of gene targeting.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11520247     DOI: 10.2165/00063030-200115060-00002

Source DB:  PubMed          Journal:  BioDrugs        ISSN: 1173-8804            Impact factor:   5.807


  3 in total

1.  Analysis of the expression of coxsackievirus and adenovirus receptor in five colon cancer cell lines.

Authors:  Yassan Abdolazimi; Majid Mojarrad; Mehrdad Pedram; Mohammad Hossein Modarressi
Journal:  World J Gastroenterol       Date:  2007-12-21       Impact factor: 5.742

2.  Specific CEA-producing colorectal carcinoma cell killing with recombinant adenoviral vector containing cytosine deaminase gene.

Authors:  Li-Zong Shen; Wen-Xi Wu; De-Hua Xu; Zhong-Cheng Zheng; Xin-Yuan Liu; Qiang Ding; Yi-Bing Hua; Kun Yao
Journal:  World J Gastroenterol       Date:  2002-04       Impact factor: 5.742

3.  PEGylated adenoviruses for gene delivery to the intestinal epithelium by the oral route.

Authors:  Xuan Cheng; Xin Ming; Maria A Croyle
Journal:  Pharm Res       Date:  2003-09       Impact factor: 4.200

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.